Investor Presentaiton
For personal use only
Building on the IPAX-1 experience
IPAX-2 will evaluate TLX101 in newly-diagnosed patients
•
•
•
•
•
Progression of TLX101 program into front-line setting, Phase I/II study
expected to commence in Q1 2022
Initial dose finding study TLX101 plus standard of care (SOC) in patients with
newly diagnosed glioblastoma, after surgery
Evaluates the potential for DNA damage from targeted radiation using TLX101 to
enhance SOC radio-chemotherapy for newly diagnosed glioma
Study objectives expected to include:
.
•
.
Maximum tolerated dose
Safety and tolerability in combination with the Stupp regimen (SOC)
12 months overall survival rates
Progression free survival at a range of treatment intervals
Single-arm, multi-centre trial, expected to enrol 12-15 patients in Phase I
Patients to be treated and monitored for up to 64 weeks
Telix Pharmaceuticals Limited (ASX: TLX)
48
TELIX
PHARMACEUTICALSView entire presentation